Claims
- 1. A carboxamide compound of the formula ##STR48## and the pharmaceutically-acceptable salts thereof; wherein R.sup.1 is selected from the group consisting of hydrogen, alkyl having 1 to 4 carbons, and --CH.sub.2 --CH.sub.2 --NR.sup.3 R.sup.4, wherein R.sup.3 and R.sup.4 are each alkyl having 1 to 3 carbons;
- R.sup.2 is selected from the group consisting of alkyl having 8 to 15 carbons and cycloalkyl having from 6 to 12 carbons;
- and X is selected from the group consisting of cis-vinylene, ethylene and ##STR49## wherein R.sup.7 and R.sup.8 are each selected from the group consisting of hydrogen and methyl;
- with the proviso that the two groups attached to the ##STR50## group must have a trans relationship to each other.
- 2. A compound according to claim 1, wherein R.sup.1 is hydrogen.
- 3. A compound according to claim 2, wherein R.sup.2 is said alkyl.
- 4. A compound according to claim 3, wherein X is cis-vinylene.
- 5. The compound according to claim 4, wherein R.sup.2 is decyl, and the two substituents on the phenyl ring have a para relationship to each other.
- 6. A compound according to claim 3, wherein X is --CH.sub.2 CH.sub.2 CH.sub.2 --.
- 7. The compound according to claim 6, wherein R.sup.2 is octyl, and the two substituents on the phenyl ring have a para relationship to each other.
- 8. A method of antagonizing the effect of slow-reacting substance of anaphylaxis in a human subject, which comprises administering to said human subject a slow-reacting substance of anaphylaxis antagonizing amount of a carboxamide compound of the formula ##STR51## or a pharmaceutically-acceptable salt thereof; wherein R.sup.1 is selected from the group consisting of hydrogen, alkyl having 1 to 4 carbons, and --CH.sub.2 --CH.sub.2 --NR.sup.3 R.sup.4, wherein R.sup.3 and R.sup.4 are each alkyl having 1 to 3 carbons;
- R.sup.2 is selected from the group consisting of alkyl having 8 to 15 carbons and cycloalkyl having from 6 to 12 carbons;
- and X is selected from the group consisting of cis-vinylene, ethylene and ##STR52## wherei R.sup.7 and R.sup.8 are each selected from the group consisting of hydrogen and methyl;
- with the proviso that the two groups attached to the ##STR53## group must have a trans relationship to each other.
- 9. A pharmaceutical composition, which comprises a pharmaceutically-acceptable carrier and a carboxamide compound of the formula ##STR54## or a pharmaceutically-acceptable salt thereof; wherein R.sup.1 is selected from the group consisting of hydrogen, alkyl having 1 to 4 carbons, and --CH.sub.2 --CH.sub.2 --NR.sup.3 R.sup.4, wherein R.sup.3 and R.sup.4 are each alkyl having 1 to 3 carbons;
- R.sup.2 is selected from the group consisting of alkyl having 8 to 15 carbons and cycloalkyl having from 6 to 12 carbons;
- and X is selected from the group consisting of cis-vinylene, ethylene and ##STR55## wherein R.sup.7 and R.sup.8 are each selected from the group consisting of hydrogen and methyl;
- with the proviso that the two groups attached to the ##STR56## group must have a trans relationship to each other; and wherein the ratio of pharmaceutically-acceptable carrier to the carboxamide compound is in the range from 1:6 to 6:1 by weight.
CROSS-REFERENCE TO RELATED APPLICATIONS
This application is a continuation-in-part of application Ser. No. 201,894, filed Oct. 29, 1980, now U.S. Pat. No. 4,296,129.
US Referenced Citations (1)
Number |
Name |
Date |
Kind |
3966965 |
Sellstedt et al. |
Jun 1976 |
|
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
201894 |
Oct 1980 |
|